LANTHEUS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.02 USD | +0.16% |
|
+0.65% | +22.61% |
Presentation Operator MessageOperator (Operator)Good morning. Welcome to the Lantheus Second Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
76.02
USD
Average target price
104.9
USD
Spread / Average Target
+37.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.61% | 5.27B | |
| -1.29% | 12.64B | |
| -0.47% | 8.46B | |
| +5.68% | 5.66B | |
| -2.03% | 4.49B | |
| -53.56% | 3.11B | |
| +19.30% | 2.87B | |
| +33.07% | 2.31B | |
| -8.42% | 2.23B | |
| -3.55% | 1.89B |
- Stock Market
- Equities
- LNTH Stock
- News Lantheus Holdings, Inc.
- Transcript : Lantheus Holdings, Inc., Q2 2023 Earnings Call, Aug 03, 2023
